Published: April
4, 2013
HOUSTON, April
4, 2013 — /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today provided an
update on its recent submission to the Centers for Medicare & Medicaid
Services ("CMS") seeking reimbursement coverage for the
treatment-resistant depression ("TRD") indication for the VNS Therapy®
System.
As previously
announced, the company submitted a request to CMS for reconsideration of
coverage for VNS Therapy for TRD and expected to receive a formal
acknowledgment from CMS accepting or rejecting its request by the end of March
2013. To date, the company has not received a formal response from CMS, but is
engaged in an ongoing dialogue regarding the reconsideration request. At
this time, the timing and ultimate outcome of the dialogue is uncertain.
"We believe
the total body of evidence that began appearing in the scientific literature in
2000 presents compelling rationale for access to VNS Therapy in a very ill
subpopulation of Medicare beneficiaries," said Dan Moore, Cyberonics'
President and Chief Executive Officer. "We look forward to continuing
our discussion with CMS with the objective of securing this access, although
there can be no assurance that the coverage objectives will be met."
No comments:
Post a Comment